VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | BET inhibition as a novel targeted therapy for myelofibrosis

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the promise of BET inhibition as a novel targeted therapy in patients with myelofibrosis (MF). Dr Masarova first highlights some findings from the MANIFEST trial (NCT02158858), evaluating the safety and efficacy of pelabresib, a BET inhibitor, in combination with ruxolitinib in patients with MF. Dr Masarova then discusses the ongoing MANIFEST-2 trial (NCT04603495), and concludes by highlighting various ways of incorporating pelabresib in MF treatment. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter